130 related articles for article (PubMed ID: 7923170)
1. 6-Thioguanine-induced growth arrest in 6-mercaptopurine-resistant human leukemia cells.
Morgan CJ; Chawdry RN; Smith AR; Siravo-Sagraves G; Trewyn RW
Cancer Res; 1994 Oct; 54(20):5387-93. PubMed ID: 7923170
[TBL] [Abstract][Full Text] [Related]
2. Guanine analog-induced differentiation of human promyelocytic leukemia cells and changes in queuine modification of tRNA.
Kretz KA; Katze JR; Trewyn RW
Mol Cell Biol; 1987 Oct; 7(10):3613-9. PubMed ID: 3479681
[TBL] [Abstract][Full Text] [Related]
3. Some biochemical characteristics of L1210 cell lines resistant to 6-mercaptopurine and 6-thioguanine and with increased sensitivity to methotrexate.
Strobel-Stevens JD; El Dareer SM; Trader MW; Hill DL
Biochem Pharmacol; 1982 Oct; 31(19):3133-7. PubMed ID: 6890814
[TBL] [Abstract][Full Text] [Related]
4. Thioguanine, mercaptopurine: their analogs and nucleosides as antimetabolites.
Elgemeie GH
Curr Pharm Des; 2003; 9(31):2627-42. PubMed ID: 14529546
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and metabolism of thiopurines in children with acute lymphoblastic leukemia receiving 6-thioguanine versus 6-mercaptopurine.
Erb N; Harms DO; Janka-Schaub G
Cancer Chemother Pharmacol; 1998; 42(4):266-72. PubMed ID: 9744770
[TBL] [Abstract][Full Text] [Related]
6. Queuine, a tRNA anticodon wobble base, maintains the proliferative and pluripotent potential of HL-60 cells in the presence of the differentiating agent 6-thioguanine.
French BT; Patrick DE; Grever MR; Trewyn RW
Proc Natl Acad Sci U S A; 1991 Jan; 88(2):370-4. PubMed ID: 1988936
[TBL] [Abstract][Full Text] [Related]
7. 6-ethylmercaptopurine-mediated growth inhibition of HL-60 cells in vitro irrespective of purine salvage.
Gibboney DS; French BT; Patrick DE; Trewyn RW
Cancer Chemother Pharmacol; 1989; 25(3):189-94. PubMed ID: 2598410
[TBL] [Abstract][Full Text] [Related]
8. Flow cytometric enumeration of drug-resistant tumor cells.
deFazio A; Musgrove EA; Tattersall MH
Cancer Res; 1988 Nov; 48(21):6037-43. PubMed ID: 3167854
[TBL] [Abstract][Full Text] [Related]
9. Thiopurine Enhanced ALL Maintenance (TEAM): study protocol for a randomized study to evaluate the improvement in disease-free survival by adding very low dose 6-thioguanine to 6-mercaptopurine/methotrexate-based maintenance therapy in pediatric and adult patients (0-45 years) with newly diagnosed B-cell precursor or T-cell acute lymphoblastic leukemia treated according to the intermediate risk-high group of the ALLTogether1 protocol.
Toksvang LN; Als-Nielsen B; Bacon C; Bertasiute R; Duarte X; Escherich G; Helgadottir EA; Johannsdottir IR; Jónsson ÓG; Kozlowski P; Langenskjöld C; Lepik K; Niinimäki R; Overgaard UM; Punab M; Räty R; Segers H; van der Sluis I; Smith OP; Strullu M; Vaitkevičienė G; Wik HS; Heyman M; Schmiegelow K
BMC Cancer; 2022 May; 22(1):483. PubMed ID: 35501736
[TBL] [Abstract][Full Text] [Related]
10. Thiopurine analogue inhibitors of severe acute respiratory syndrome-coronavirus papain-like protease, a deubiquitinating and deISGylating enzyme.
Chen X; Chou CY; Chang GG
Antivir Chem Chemother; 2009; 19(4):151-6. PubMed ID: 19374142
[TBL] [Abstract][Full Text] [Related]
11. Characterization of differentiation-inducer-resistant HL-60 cells.
Gallagher RE; Bilello PA; Ferrari AC; Chang CS; Yen RW; Nickols WA; Muly EC
Leuk Res; 1985; 9(8):967-86. PubMed ID: 3862924
[TBL] [Abstract][Full Text] [Related]
12. Delayed cytotoxicity of 6-mercaptopurine is compatible with mitotic death caused by DNA damage due to incorporation of 6-thioguanine into DNA as 6-thioguanine nucleotide.
Inamochi H; Higashigawa M; Shimono Y; Nagata T; Cao DC; Mao XY; M'soka T; Hori H; Kawasaki H; Sakurai M
J Exp Clin Cancer Res; 1999 Sep; 18(3):417-24. PubMed ID: 10606189
[TBL] [Abstract][Full Text] [Related]
13. Evidence for a connection between the mismatch repair system and the G2 cell cycle checkpoint.
Hawn MT; Umar A; Carethers JM; Marra G; Kunkel TA; Boland CR; Koi M
Cancer Res; 1995 Sep; 55(17):3721-5. PubMed ID: 7641183
[TBL] [Abstract][Full Text] [Related]
14. Quantification of Thiopurine Nucleotides in Erythrocytes and Clinical Application to Pediatric Acute Lymphoblastic Leukemia.
Moon SY; Lim JH; Kim EH; Nam Y; Yu KS; Hong KT; Choi JY; Hong CR; Kim H; Kang HJ; Shin HY; Lee K; Song J; Lee SY; Song SH
Ther Drug Monit; 2019 Feb; 41(1):75-85. PubMed ID: 30507626
[TBL] [Abstract][Full Text] [Related]
15. Effect of 6-thioguanine on Chlamydia trachomatis growth in wild-type and hypoxanthine-guanine phosphoribosyltransferase-deficient cells.
Qin B; McClarty G
J Bacteriol; 1992 May; 174(9):2865-73. PubMed ID: 1569017
[TBL] [Abstract][Full Text] [Related]
16. Combined preconditioning and in vivo chemoselection with 6-thioguanine alone achieves highly efficient reconstitution of normal hematopoiesis with HPRT-deficient bone marrow.
Hacke K; Szakmary A; Cuddihy AR; Rozengurt N; Lemp NA; Aubrecht J; Lawson GW; Rao NP; Crooks GM; Schiestl RH; Kasahara N
Exp Hematol; 2012 Jan; 40(1):3-13.e3. PubMed ID: 22001673
[TBL] [Abstract][Full Text] [Related]
17. The cytotoxicity of thioguanine vs mercaptopurine in acute lymphoblastic leukemia.
Adamson PC; Poplack DG; Balis FM
Leuk Res; 1994 Nov; 18(11):805-10. PubMed ID: 7967706
[TBL] [Abstract][Full Text] [Related]
18. DNA-thioguanine nucleotide as a treatment marker in acute lymphoblastic leukemia patients with NUDT15 variant genotypes.
Ju HY; Lee JW; Cho HW; Hyun JK; Ma Y; Yi ES; Yoo KH; Sung KW; Choi R; Koo HH; Lee SY
PLoS One; 2021; 16(1):e0245667. PubMed ID: 33481917
[TBL] [Abstract][Full Text] [Related]
19. Biochemical basis of the prevention of 6-thiopurine toxicity by the nucleobases, hypoxanthine and adenine.
Hashimoto H; Kubota M; Shimizu T; Takimoto T; Kitoh T; Akiyama Y; Mikawa H
Leuk Res; 1990; 14(11-12):1061-6. PubMed ID: 2280604
[TBL] [Abstract][Full Text] [Related]
20. The isolation and preliminary characterisation of 6-thioguanine-resistant mutants of human diploid fibroblasts.
Cox R; Masson WK
Mutat Res; 1976 Jul; 36(1):93-104. PubMed ID: 950955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
